Posts tagged Stifel
Stifel nearly triples PT for GTx to $45 from $16

Stifel nearly tripled its price target for GTx (NASDAQ:GTXI) to $45 from $16 after the company reported significant positive new data at the SUFU Winter Meeting for its Phase 2 proof-of-concept study testing, enobosarm, in female patients with stress urinary incontinence (SUI). The stock closed at $16.81 on March 2.

Read More
Stifel ups Tetraphase to buy

Stifel upgraded Tetraphase Pharmaceuticals (NASDAQ:TTPH) to “buy” from “hold” and raised its price target to $15 from $8 after the company reported positive top-line results of the IGNITE4 clinical trial evaluating its eravacycline in patients with complicated intra-abdominal infections (cIAI). The stock closed at $6.90 on July 25.

Read More
Stifel ups Reata price target to $50

Stifel raised its price target for “buy-rated” Reata Pharmaceuticals (NASDAQ:RETA) to $50 from $38 after the company reported statistically significant improvements in kidney function from the Phase 2 portion of its Cardinal study evaluating BARD in Alport chronic kidney disease (CKD). The stock closed at $37.66 on July 24.

Read More
Stifel upgrades Durect to buy

Stifel upgraded Durect (NASDAQ:DRRX) to “buy” from “hold” and raised its price target to $3 from $1.25 and also transitioned coverage to Adam Walsh from Annabel Samimy. The stock closed at $1.59 on July 11.

Read More
Analysts starts Tocagen at buy, MP

Analysts at Stifel and Leerink initiated coverage of Tocagen (NASDAQ:TOCA) with “buy” and “market perform” ratings, and price targets of $24 and $19, respectively. The stock closed at $17.40 on May 5.

Read More
Stifel ups Esperion price target to $45

Stifel raised its price target for Esperion Therapeutics (NASDAQ:ESPR) to $45 from $30. The stock closed at $29.33 on March 2.

Read More
Stifel starts Reata Pharma at buy

Stifel launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and $38 price target. The stock closed at $23.05 on Feb. 22.

Read More
Stifel downgrades Argos to hold

Stifel downgraded Argos Therapeutics (NASDAQ:ARGS) to “hold” from “buy” and slashed its price target to $1.40 from $10 after an independent data monitoring committee (IDMC) recommended discontinuation of the ADAPT Phase 3 trial of AGS-003 in metastatic renal cell carcinoma (RCC) patients.

Read More
Stifel ups Momenta price target to $30

Stifel raised its price target for Momenta Pharmaceuticals (NASDAQ:MNTA) to $30 from $20 after a district court yesterday afternoon ruled that Teva Pharmaceutical’s Copaxone Q3W patents were invalid due to obviousness. The stock closed at $15.10 on Jan. 30.

Read More
Stifel downgrades Ocera Therapeutics to hold

Stifel downgraded Ocera Therapeutics (NASDAQ:OCRX) to “hold” from “buy” and slashed its price target to $1 from $9 after the company reported top-line results from a Phase 2b study evaluating ornithine phenylacetate (OCR-002) in hospitalized patients with hepatic encephalopathy (HE).

Read More